Benchling

❌ Legacy systems are no longer enough. At the Benchling Development Summit, #biopharma leaders gathered to discuss how to use technology to accelerate clinical timelines. Axendia, Inc.’s report shares key takeaways — including how Merck modernized their vaccine development program, with measurable impact to their vaccine bioanalysis team: ✔️ 10x efficiency boost ✔️ 25% reduction in tedious tasks ✔️ 6 legacy systems phased out 👉 Get the report: https://xmrrwallet.com/cmx.plnkd.in/eC4EDAtq Thanks to the Axendia team: Daniel Matlis, Sandra Rodriguez, Mónica V. M., and Kelly Doering.

💡 From local breakthroughs to global success stories, how is France shaping the future of R&D? Find out at our annual Paris Digital Science & Innovation Day. Join over 200 scientists, R&D leaders, and digital experts for a high-energy day of real-world case studies, interactive panels, and peer-led discussions. 🇫🇷 Don’t miss France’s premier event for #biopharma innovators — register today: https://xmrrwallet.com/cmx.plnkd.in/eR3fb7C8 #ParisDigitalScienceDay

🧠 “As human beings, we like to believe we are more innovative than a computational model,” says Jannick Bendtsen, Head of PipeBio. “But I’m not sure about that. In the future, I believe we will use AI to come up with completely new therapeutic proteins.” #AI/ML are already driving innovation in antibody discovery — from predicting target interactions to improving process development. Find out how computation is reshaping the biologics pipeline. 📖 Download the report: https://xmrrwallet.com/cmx.plnkd.in/eGmuxfA4

⛏️🚫 Stop digging through lab notebooks, PDFs, and papers. Benchling’s Deep Research extracts insights by reasoning across your own experimental data and public literature. It’s like a co-scientist that can synthesize years of experimental knowledge — across your company and outside it. It’s about better questions, faster answers. ✨ Check out our #AI assistants: https://xmrrwallet.com/cmx.plnkd.in/e-f_9xYe #FeatureFriday #BenchlingAssistants

🎤 What’s #Benchtalk really like? It’s more than an event. It’s where the #biotech community comes together to swap real-world tips, spark new ideas, and move science forward, together. Hear why past attendees keep coming back — and why you won’t want to miss it. Register now: 📍 Benchtalk Boston: https://xmrrwallet.com/cmx.plnkd.in/eB2wemsH 📍 Benchtalk Europe: https://xmrrwallet.com/cmx.plnkd.in/erx5aUHj

🎙️ Hear from John Tsai, MD — physician, engineer, former CMO at Novartis, and strategic force behind over 15 drug approvals. He’s shaped blockbusters, launched gene therapies, and now leads Forcefield Therapeutics. 👉 In this interview with Benchling CEO Sajith Wickramasekara, John shares the story behind the first FDA-approved CAR T therapy — and what it takes to stay bold when the stakes are high: https://xmrrwallet.com/cmx.plnkd.in/gzYxT3PJ  #Transcribed

📈 The global #antibody therapeutics market is valued at $250B — and projected to exceed $850B within the next decade. And yet, discovery remains complex, time-consuming, and expensive. What’s the path forward? Explore where #AI/ML is making huge strides antibody discovery — and where it falls short: ✨ Predicting antibody properties and target interactions ✨ Correcting an antibody’s structure early on ✨ Improving patient responsiveness ✨ Designing de novo therapeutic antibodies 📖 Download the report: https://xmrrwallet.com/cmx.plnkd.in/eGmuxfA4

😵💫 From chaos to clarity — in seconds. Let our #AI assistant convert your messy PDFs, docs, and spreadsheets into clean, structured, analysis-ready data in Benchling. Less clicking, more science. It’s hassle-free data capture. ✨ See what else we’re building: https://xmrrwallet.com/cmx.plnkd.in/e-f_9xYe #FeatureFriday #BenchlingAssistants

When it comes to Chinese biotechs, the capabilities are very real. Patrick Hsu explains why the U.S. shouldn’t try to compete with China on biomanufacturing — the future of American biotech depends instead on innovation, data, and #AI. 👉 Watch his interview with Benchling CEO Sajith Wickramasekara for more hot takes on the future of drug discovery: https://xmrrwallet.com/cmx.plnkd.in/e2_zvVh8 #Transcribed

From huge blockbusters like Lipitor to the first FDA-approved CAR T, John Tsai, MD has been a driving force behind some of the biggest breakthroughs of our time. As former CMO at Novartis, he led over 500 clinical trials, leading to 15 new drug approvals. John has seen it all, and that’s why I was thrilled to interview him live in front of a few hundred scientists. We talk about his journey from engineering to medicine, the drugs that almost didn’t make it, and how to push controversial, high-risk programs across the finish line. Check it out: https://xmrrwallet.com/cmx.plnkd.in/gWm9-epP